Gene, Cell and Tissue

Published by: Kowsar

Serum Levels of Interleukin-27 and Interleukin-33 in Patients With Dermatomyositis and Polymyositis Compared to Healthy Control Subjects

Gellare Shahryari 1 , Ali Shahraki 1 , * and Zahra Zakeri 2
Authors Information
1 Department of Biology, Faculty of Sciences, University of Sistan and Baluchestan, Zahedan, IR Iran
2 Department of Internal Medicine, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
Article information
  • Gene, Cell and Tissue: October 01, 2015, 2 (4); e31087
  • Published Online: October 18, 2015
  • Article Type: Research Article
  • Received: June 27, 2015
  • Revised: August 10, 2015
  • Accepted: August 30, 2015
  • DOI: 10.17795/gct-31087

To Cite: Shahryari G, Shahraki A, Zakeri Z. Serum Levels of Interleukin-27 and Interleukin-33 in Patients With Dermatomyositis and Polymyositis Compared to Healthy Control Subjects, Gene Cell Tissue. 2015 ; 2(4):e31087. doi: 10.17795/gct-31087.

Abstract
Copyright © 2015, Zahedan University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
Footnote
References
  • 1. Hak AE, de Paepe B, de Bleecker JL, Tak PP, de Visser M. Dermatomyositis and polymyositis: new treatment targets on the horizon. Neth J Med. 2011; 69(10): 410-21[PubMed]
  • 2. Castro C, Gourley M. Diagnosis and treatment of inflammatory myopathy: issues and management. Ther Adv Musculoskelet Dis. 2012; 4(2): 111-20[DOI][PubMed]
  • 3. Sugiura T, Harigai M, Kawaguchi Y, Takagi K, Fukasawa C, Ohsako-Higami S, et al. Increased IL-15 production of muscle cells in polymyositis and dermatomyositis. Int Immunol. 2002; 14(8): 917-24[PubMed]
  • 4. Mielnik P, Chwalinska-Sadowska H, Wiesik-Szewczyk E, Maslinski W, Olesinska M. Serum concentration of interleukin 15, interleukin 2 receptor and TNF receptor in patients with polymyositis and dermatomyositis: correlation to disease activity. Rheumatol Int. 2012; 32(3): 639-43[DOI][PubMed]
  • 5. Villarino AV, Huang E, Hunter CA. Understanding the pro- and anti-inflammatory properties of IL-27. J Immunol. 2004; 173(2): 715-20[PubMed]
  • 6. Kastelein RA, Hunter CA, Cua DJ. Discovery and biology of IL-23 and IL-27: related but functionally distinct regulators of inflammation. Annu Rev Immunol. 2007; 25: 221-42[DOI][PubMed]
  • 7. Yoshida H, Miyazaki Y. Regulation of immune responses by interleukin-27. Immunol Rev. 2008; 226: 234-47[DOI][PubMed]
  • 8. Smith DE. IL-33: a tissue derived cytokine pathway involved in allergic inflammation and asthma. Clin Exp Allergy. 2010; 40(2): 200-8[DOI][PubMed]
  • 9. Lamkanfi M, Dixit VM. IL-33 raises alarm. Immunity. 2009; 31(1): 5-7[DOI][PubMed]
  • 10. Ali S, Mohs A, Thomas M, Klare J, Ross R, Schmitz ML, et al. The dual function cytokine IL-33 interacts with the transcription factor NF-kappaB to dampen NF-kappaB-stimulated gene transcription. J Immunol. 2011; 187(4): 1609-16[DOI][PubMed]
  • 11. Shen H, Xia L, Xiao W, Lu J. Increased levels of interleukin-27 in patients with rheumatoid arthritis. Arthritis Rheum. 2011; 63(3): 860-1[DOI][PubMed]
  • 12. Shahraki A, Zakeri Z, Hossenian M, Hajnegad S. Interleukin-33 and Interleukin-18 serum levels in patients with rheumatoid arthritis and osteoporesis. J Birjand Univ Med Sci. 2014; 21(1): 86-95
  • 13. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975; 292(7): 344-7[DOI][PubMed]
  • 14. Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med. 1975; 292(8): 403-7[DOI][PubMed]
  • 15. Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet. 2003; 362(9388): 971-82[DOI][PubMed]
  • 16. Ishii W, Matsuda M, Shimojima Y, Itoh S, Sumida T, Ikeda S. Flow cytometric analysis of lymphocyte subpopulations and TH1/TH2 balance in patients with polymyositis and dermatomyositis. Intern Med. 2008; 47(18): 1593-9[PubMed]
  • 17. Yuan L, Yao L, Zhao L, Xia L, Shen H, Lu J. Serum levels of soluble ST2 and interleukin-33 in patients with dermatomyositis and polymyositis. Clin Exp Rheumatol. 2013; 31(3): 428-32[PubMed]
  • 18. Wojno ED, Hunter CA. New directions in the basic and translational biology of interleukin-27. Trends Immunol. 2012; 33(2): 91-7[DOI][PubMed]
  • 19. Shen H, Xia L, Lu J. Pilot study of interleukin-27 in pathogenesis of dermatomyositis and polymyositis: associated with interstitial lung diseases. Cytokine. 2012; 60(2): 334-7[DOI][PubMed]
  • 20. Cao Y, Doodes PD, Glant TT, Finnegan A. IL-27 induces a Th1 immune response and susceptibility to experimental arthritis. J Immunol. 2008; 180(2): 922-30[PubMed]
  • 21. Baek SH, Lee SG, Park YE, Kim GT, Kim CD, Park SY. Increased synovial expression of IL-27 by IL-17 in rheumatoid arthritis. Inflamm Res. 2012; 61(12): 1339-45[DOI][PubMed]
  • 22. Hong YS, Moon SJ, Joo YB, Jeon CH, Cho ML, Ju JH, et al. Measurement of interleukin-33 (IL-33) and IL-33 receptors (sST2 and ST2L) in patients with rheumatoid arthritis. J Korean Med Sci. 2011; 26(9): 1132-9[DOI][PubMed]
  • 23. Yuan FL, Li X, Lu WG, Li CW, Xu RS, Dong J. IL-33: a promising therapeutic target for rheumatoid arthritis? Expert Opin Ther Targets. 2011; 15(5): 529-34[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments